Qualigen Therapeutics Inc

NASDAQ:QLGN

1.01

+0.03 (+3.05%)

4:42:40 PM EDT: $0.98 -0.03 (-2.90%)

Market Cap (Intraday)	5.26M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.5 Million
Adjusted EPS	-$0.92

See more estimates

10-Day MA	$1.01
50-Day MA	$1.05
200-Day MA	$1.08

See more pivots

Qualigen Therapeutics Inc Stock, NASDAQ:QLGN

2042 Corte Del Nogal, Suite 3000, Carlsbad, California 92011

United States of America

Phone: +1.760.918.9165

Number of Employees: 38

http://www.qualigeninc.com

Description

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.